In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On a base area of 55,000 m2, the park now hosts 50 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics
Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics. The leading...
Results published of PROPOSe, a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision making in prostate cancer
Zurich-Schlieren, Switzerland, January 07, 2021 - Proteomedix, the Swiss cancer diagnostics company, announced today that the results of PROPOSe, a prospective multicenter study of Proclarix® in clinical routine use, were published in European Urology Oncology1). Prostate specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or...